Supreme Court Curbs Public’s Right to Sue Pesticide Makers Over Failure-to-Warn Claims

The U.S. Supreme Court recently delivered a landmark 7-2 decision in Monsanto v. Durnell, effectively eliminating a long-standing right for individuals to pursue "failure-to-warn" claims against pesticide manufacturers in state courts. This ruling significantly limits the ability of consumers to hold companies accountable when their products, even if approved by the Environmental Protection Agency (EPA) without a cancer warning, are later alleged to cause severe health issues such as cancer or other diseases. The decision has profound implications for ongoing mass tort litigation, particularly the tens of thousands of lawsuits linking Bayer’s glyphosate-based herbicide, Roundup, to non-Hodgkin lymphoma (NHL).

Background to the Litigation: Glyphosate, Cancer, and Corporate Accountability

The core of the legal battle revolves around glyphosate, the active ingredient in Roundup, which was first introduced by Monsanto (now owned by Bayer AG) in 1974. Roundup became one of the most widely used herbicides globally, praised for its effectiveness in weed control. However, scientific and public concern escalated following a 2015 classification by the International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO), which declared glyphosate a "probable human carcinogen." This assessment sharply contrasted with the EPA’s consistent stance, which has maintained that glyphosate is "not likely to be carcinogenic to humans" when used as directed.

This divergence in scientific opinion fueled a torrent of lawsuits across the United States. Plaintiffs, primarily farmers, landscapers, and gardeners, alleged that their prolonged exposure to Roundup caused them to develop non-Hodgkin lymphoma. A key component of these lawsuits was the "failure-to-warn" claim under state tort law. This legal theory posits that a manufacturer has a duty to warn consumers about potential health risks associated with its product, and failure to do so, when the manufacturer knew or should have known of such risks, constitutes negligence. Juries in several high-profile trials found Monsanto liable for failing to warn consumers, awarding billions in damages, though these amounts were often reduced on appeal.

Monsanto, acquired by Bayer AG in 2018 for approximately $63 billion, inherited this massive legal liability. The acquisition, one of the largest in corporate history, was largely driven by Monsanto’s dominant position in agricultural chemicals and seeds, but it also brought with it the looming shadow of the Roundup litigation. Bayer has consistently denied the carcinogenicity of glyphosate, citing numerous regulatory reviews worldwide that have deemed the chemical safe.

The Supreme Court’s Decision in Monsanto v. Durnell

The Durnell case, a representative appeal from the broader Roundup litigation, presented the Supreme Court with a critical question: Does the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempt state-level failure-to-warn claims against pesticide manufacturers? FIFRA is the federal statute governing the registration, labeling, and sale of pesticides in the U.S., requiring manufacturers to register their products with the EPA and ensure labels comply with federal standards.

In its 7-2 ruling, the Supreme Court’s majority sided with Monsanto/Bayer, affirming that if the EPA has approved a pesticide’s label without requiring a cancer warning, state law claims alleging "failure to warn" about cancer risks are preempted, or prohibited. The majority opinion argued that allowing state courts to mandate warnings not required by the EPA would undermine FIFRA’s comprehensive federal regulatory scheme. Essentially, the Court held that federal law, specifically the EPA’s authority under FIFRA, takes precedence over state common law claims in this context.

Justice Neil Gorsuch and Justice Ketanji Brown Jackson issued dissenting opinions, arguing that the majority’s interpretation of FIFRA was overly broad and misconstrued the nuances of the statute. They contended that FIFRA’s preemption provisions were not intended to eliminate all state tort remedies, particularly when federal regulators have not explicitly prohibited such warnings. Their dissent highlighted concerns about the erosion of consumer protection and the ability of individuals to seek redress for corporate malfeasance.

Immediate Reactions and Legal Implications

The Supreme Court’s decision sent immediate ripples through the legal and financial markets. Bayer AG’s stock surged by 17% on the day of the ruling, signaling investor confidence that the company’s substantial legal liabilities would be significantly reduced. For Bayer, the ruling represents a monumental victory, potentially curtailing a significant portion of its remaining legal exposure.

Carey Gillam, editor-in-chief at The New Lede and a prominent author who has extensively covered the Monsanto trials, offered insights into the ruling’s complex reception. "Bayer is celebrating this ruling because the company believes that this will put an end to the lawsuits that are still outstanding," Gillam told Corporate Crime Reporter. "They believe that without the failure-to-warn claims, the lawsuits become much more difficult for the plaintiffs to prevail — and that plaintiffs are much more likely to settle and that people will be less likely to sue them in the future."

However, the sentiment among plaintiffs’ attorneys is far from uniform. While acknowledging the severe blow to the "failure-to-warn" claims, some attorneys maintain that other legal avenues remain viable. "There are a number of plaintiffs attorneys who say — we have lost failure to warn, but we still can sue on other grounds — that the company was negligent, they didn’t design their products properly — it’s more dangerous than can reasonably be expected," Gillam explained. These "design defect" or "negligence" claims argue that the product itself was inherently unsafe, regardless of the warning label.

Despite these alternative claims, Gillam underscored the practical challenges. "The failure-to-warn claim is something that is foundational to much of this litigation. It’s easy for juries to understand. Here is the science, there is abundant scientific research out that shows a connection, that shows that at least it’s possible… Why didn’t the company put that on the product, like a tobacco warning label? That resonated with jurors." The more technical arguments required for design defect claims are often harder for juries to grasp, potentially increasing the complexity and cost of litigation for plaintiffs’ firms, making them less likely to pursue such cases in the future.

The Center for Food Safety (CFS), a leading legal nonprofit advocating for food and agriculture issues, strongly condemned the ruling. George Kimbrell, legal director at CFS, stated, "Overturning decades of well-settled law, the Supreme Court eliminated one way the public held pesticide corporations accountable for their products’ harms. But the fight is far from over. EPA’s regulation of pesticides just became all the more vital to protecting the public health and public interest. We will continue to hold EPA accountable when it does not." CFS had filed an amicus brief in the Supreme Court case on behalf of a broad coalition of public interest stakeholders, including farmers, farmworkers, medical professionals, and consumer protection advocates.

The Broader Litigation Landscape: Settlements and Controversies

Before the Supreme Court’s decision, Bayer had already allocated significant funds to address the massive influx of Roundup lawsuits. The company estimates that it has resolved the vast majority of the initial 170,000 claims, having paid over $11 billion in settlements and verdicts. However, an estimated 50,000 to 60,000 claims may still be outstanding.

The litigation has unfolded through a complex structure, primarily involving multi-district litigation (MDL) and ongoing efforts to establish a class action settlement. In an MDL, individual lawsuits are consolidated before one judge for pretrial proceedings, such as discovery and expert witness testimony, to streamline the process. However, each case retains its individual identity and, if not settled, would typically return to its home court for trial. This is distinct from a class action, where a large group of individuals with similar claims are treated as a single entity, and a settlement or judgment applies to the entire class.

Bayer has been actively pursuing a class action settlement to resolve future claims and put the litigation behind it definitively. The company has offered another $7.25 billion to settle a proposed class action that would encompass all individuals currently suing, those intending to sue, and even those who might develop cancer and wish to sue in the future.

This proposed class action settlement has been met with significant controversy. Judge Vince Chhabria, who oversees the Roundup MDL in California, famously described the proposed deal as "filthy" and "very unfair." He criticized the structure, which he believed disproportionately benefited the handful of plaintiffs’ attorneys who brokered the deal with Bayer, while offering potentially meager payouts of "a few thousands dollars each" to the actual cancer victims. The judge also noted that the attorneys who led the initial, successful trials against Monsanto were not involved in negotiating this class action settlement, leading to "a lot of animosity" among plaintiff lawyers.

The Supreme Court’s Durnell ruling now adds another layer of complexity to these ongoing settlement discussions. Plaintiffs and their attorneys who previously opted out of the class action settlement, hoping for a more substantial individual verdict, must now re-evaluate their positions. The elimination of the potent "failure-to-warn" claim reduces their leverage in court, potentially making the class action settlement, however imperfect, a more palatable option for some. A critical hearing on the class action settlement is scheduled for July 9, which will shed more light on how many plaintiffs are opting in or out. Bayer has indicated it may walk away from the settlement if a sufficient number of plaintiffs do not agree to its terms.

Legislative Efforts to Counter the Ruling

In response to the Supreme Court’s decision, legislative efforts are already underway to restore the public’s right to sue. Senator Cory Booker and Congresswoman Chellie Pingree are prominent figures in this movement. Congresswoman Pingree has introduced legislation that would amend FIFRA, explicitly stating that federal law does not preempt state failure-to-warn claims, thereby aiming to undo the Supreme Court’s ruling. Senator Booker has explored adding a similar amendment to the Farm Bill, a comprehensive piece of legislation that governs agricultural policy.

These legislative initiatives face an uphill battle against the formidable lobbying power of the agricultural chemical industry in Washington, D.C. However, they are bolstered by growing grassroots movements, such as the "Make America Healthy Again" (MAHA) coalition and "mad moms" who are pledging to mobilize on Capitol Hill and make this a significant issue in upcoming elections. This public pressure could potentially sway lawmakers, highlighting the ongoing tension between corporate interests, federal regulation, and public health advocacy.

Broader Implications for Public Health and Corporate Accountability

The Monsanto v. Durnell decision represents a significant shift in the landscape of corporate accountability for products regulated by federal agencies. By strengthening the preemption doctrine, the Supreme Court has effectively placed greater responsibility on federal regulators, primarily the EPA in this instance, to ensure product safety and adequate consumer warnings. If the EPA does not require a warning, companies may now face reduced legal exposure in state courts, even if independent scientific bodies or future research suggests a health risk.

This ruling could incentivize corporations to lobby federal agencies more aggressively to avoid warning requirements, knowing that EPA approval could serve as a shield against state tort claims. Critics argue that this places an undue burden on federal agencies, which may have limited resources or be susceptible to political influence, and removes a crucial layer of accountability provided by the civil justice system.

Conversely, proponents of the ruling argue that it provides regulatory certainty for industries, preventing a patchwork of conflicting state laws and potentially contradictory jury verdicts that could complicate interstate commerce and product development. They maintain that a single federal standard is more efficient and predictable.

The decision’s long-term impact on public health could be substantial. If manufacturers are less vulnerable to "failure-to-warn" lawsuits, there may be less incentive for them to proactively investigate and disclose potential health risks associated with their products beyond what federal regulators explicitly mandate. This could potentially leave consumers exposed to undisclosed dangers for longer periods.

Looking Ahead: The Paraquat Litigation

The ripple effects of the Monsanto v. Durnell decision are already being observed in other toxic tort cases. Carey Gillam pointed to the ongoing paraquat litigation as the next major front. Paraquat, another widely used weedkiller, is now the subject of a similar MDL, with plaintiffs alleging it causes Parkinson’s disease.

The paraquat litigation is following a path akin to Roundup’s, albeit on a smaller and newer scale. However, it is also encountering controversial settlement pressures. Gillam highlighted a situation where Judge Nancy Rosenstengel, overseeing the paraquat MDL, is reportedly trying to "induce people to agree to a settlement with Syngenta that plaintiffs lawyers say is pitiful and is a terrible deal." The judge is allegedly attempting to compel plaintiffs who refuse the settlement to undergo extensive scrutiny, including depositions and meetings with a special master, which plaintiffs’ attorneys view as an unusual and questionable judicial effort to favor a settlement over individual trials.

The Supreme Court’s Durnell ruling will undoubtedly influence how these future cases are litigated and settled. With the "failure-to-warn" claim now largely off the table for federally regulated pesticides, plaintiffs in subsequent toxic tort actions will need to develop even stronger arguments based on design defects or other negligence theories, making the path to justice potentially more arduous and costly. The decision marks a pivotal moment in the ongoing struggle for balance between corporate innovation, regulatory oversight, and consumer protection in the United States.